These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 38458476

  • 1. Gut Immunomodulation with Vedolizumab prior to Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Inflammatory Bowel Disease.
    Chopra Y, Acevedo K, Muise A, Frost K, Schechter T, Krueger J, Ali M, Chiang KY, Kim VH, Grunebaum E, Wall D.
    Transplant Cell Ther; 2024 May; 30(5):546.e1-546.e7. PubMed ID: 38458476
    [Abstract] [Full Text] [Related]

  • 2. CD3+TCRαβ/CD19+-Depleted Mismatched Family or Unrelated Donor Salvage Stem Cell Transplantation for Graft Dysfunction in Inborn Errors of Immunity.
    Ramanathan S, Lum SH, Nademi Z, Carruthers K, Watson H, Flood T, Owens S, Williams E, Hambleton S, Gennery AR, Slatter M.
    Transplant Cell Ther; 2023 Aug; 29(8):513.e1-513.e9. PubMed ID: 37279857
    [Abstract] [Full Text] [Related]

  • 3. Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.
    Chen YB, Mohty M, Zeiser R, Teshima T, Jamy O, Maertens J, Purtill D, Chen J, Cao H, Rossiter G, Jansson J, Fløisand Y.
    Nat Med; 2024 Aug; 30(8):2277-2287. PubMed ID: 38844797
    [Abstract] [Full Text] [Related]

  • 4. Haploidentical Cord Blood Transplantation with 8 mg/kg Antithymocyte Globulin as Graft-versus-Host Disease Prophylaxis Compared to Haploidentical Transplantation with 10 mg/kg Antithymocyte Globulin in the Treatment of Acute Leukemia.
    Yuan F, Li G, Li M, Wei X, Fu Y.
    Transplant Cell Ther; 2023 Dec; 29(12):771.e1-771.e10. PubMed ID: 37748539
    [Abstract] [Full Text] [Related]

  • 5. Vedolizumab in highly resistant acute gastrointestinal graft-versus-host disease after allogeneic stem cell transplantation: A single-center pediatric series.
    Rosa M, Jarmoliński T, Miśkiewicz-Migoń I, Liszka K, Miśkiewicz-Bujna J, Panasiuk A, Frączkiewicz J, Ussowicz M.
    Adv Clin Exp Med; 2022 Mar; 31(3):345-350. PubMed ID: 35212198
    [Abstract] [Full Text] [Related]

  • 6. Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Chen YB, Shah NN, Renteria AS, Cutler C, Jansson J, Akbari M, Chen C, Quadri S, Parfionovas A, Devine SM.
    Blood Adv; 2019 Dec 10; 3(23):4136-4146. PubMed ID: 31821456
    [Abstract] [Full Text] [Related]

  • 7. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, Gutman JA, Petersen SL, Chauncey TR, Bethge WA, Pulsipher MA, Woolfrey AE, Mielcarek M, Martin PJ, Appelbaum FR, Flowers MED, Maloney DG, Storb R.
    Lancet Haematol; 2019 Aug 10; 6(8):e409-e418. PubMed ID: 31248843
    [Abstract] [Full Text] [Related]

  • 8. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS, Kwak DH, Jeon YW, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Cho SG, Kim DW, Min WS, Lee JW.
    Biol Blood Marrow Transplant; 2017 Sep 10; 23(9):1498-1508. PubMed ID: 28554856
    [Abstract] [Full Text] [Related]

  • 9. Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
    Wegener A, Andersen NS, Friis LS, Petersen SL, Schjødt I, Kornblit B, Sengeløv H, Gjærde LK.
    Transplant Cell Ther; 2023 Sep 10; 29(9):575.e1-575.e6. PubMed ID: 37301257
    [Abstract] [Full Text] [Related]

  • 10. First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia.
    Peinemann F, Bartel C, Grouven U.
    Cochrane Database Syst Rev; 2013 Jul 23; 2013(7):CD006407. PubMed ID: 23881658
    [Abstract] [Full Text] [Related]

  • 11. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide.
    Chorão P, Henriques M, Villalba M, Montoro J, Balaguer-Roselló A, González EM, Gómez MD, Gómez I, Solves P, Santiago M, Asensi P, Lamas B, Bataller A, Granados P, Eiris J, Martínez D, Louro A, Rebollar P, Perla A, Salavert M, de la Rubia J, Sanz MÁ, Sanz J.
    Transplant Cell Ther; 2024 May 23; 30(5):538.e1-538.e10. PubMed ID: 38331195
    [Abstract] [Full Text] [Related]

  • 12. Outcome of allogeneic Hematopoietic Stem Cell Transplantation on Diamond-Blackfan anemia using busulfan-based myeloablative regimen.
    Behfar M, Koochakzadeh L, Yazdanian N, Salajegheh P, Rostami T, Khodayari-Namini N, Ghavamzadeh A, Hamidieh AA.
    Turk J Pediatr; 2019 May 23; 61(3):407-412. PubMed ID: 31916719
    [Abstract] [Full Text] [Related]

  • 13. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis.
    Albert MH, Slatter MA, Gennery AR, Güngör T, Bakunina K, Markovitch B, Hazelaar S, Sirait T, Courteille V, Aiuti A, Aleinikova OV, Balashov D, Bernardo ME, Bodova I, Bruno B, Cavazzana M, Chiesa R, Fischer A, Hauck F, Ifversen M, Kałwak K, Klein C, Kulagin A, Kupesiz A, Kuskonmaz B, Lindemans CA, Locatelli F, Lum SH, Maschan A, Meisel R, Moshous D, Porta F, Sauer MG, Sedlacek P, Schulz A, Suarez F, Vallée TC, Winiarski JH, Zecca M, Neven B, Veys P, Lankester AC.
    Blood; 2022 Mar 31; 139(13):2066-2079. PubMed ID: 35100336
    [Abstract] [Full Text] [Related]

  • 14. Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.
    Gao Z, Fan Z, Liu Z, Ye X, Zeng Y, Xuan L, Huang F, Lin R, Sun J, Liu Q, Xu N.
    Front Immunol; 2024 Mar 31; 15():1408211. PubMed ID: 39021571
    [Abstract] [Full Text] [Related]

  • 15. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
    Choudhary D, Sharma SK, Gupta N, Kharya G, Pavecha P, Handoo A, Setia R, Katewa S.
    Biol Blood Marrow Transplant; 2013 Mar 31; 19(3):492-5. PubMed ID: 23160007
    [Abstract] [Full Text] [Related]

  • 16. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
    MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK, Davies SM, Blazar BR.
    Biol Blood Marrow Transplant; 2002 Mar 31; 8(7):387-94. PubMed ID: 12171485
    [Abstract] [Full Text] [Related]

  • 17. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
    Wiebking V, Hütker S, Schmid I, Immler S, Feuchtinger T, Albert MH.
    Ann Hematol; 2017 Aug 31; 96(8):1373-1377. PubMed ID: 28573314
    [Abstract] [Full Text] [Related]

  • 18. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
    Güngör T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, Vermont C, Ahmad I, Shaw PJ, Telles da Cunha JM, Schlegel PG, Hough R, Fasth A, Kentouche K, Gruhn B, Fernandes JF, Lachance S, Bredius R, Resnick IB, Belohradsky BH, Gennery A, Fischer A, Gaspar HB, Schanz U, Seger R, Rentsch K, Veys P, Haddad E, Albert MH, Hassan M, Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation.
    Lancet; 2014 Feb 01; 383(9915):436-48. PubMed ID: 24161820
    [Abstract] [Full Text] [Related]

  • 19. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
    Montoro J, Boumendil A, Finel H, Bramanti S, Castagna L, Blaise D, Dominietto A, Kulagin A, Yakoub-Agha I, Tbakhi A, Solano C, Giebel S, Gulbas Z, López Corral L, Pérez-Simón JA, Díez Martín JL, Sanz J, Farina L, Koc Y, Socié G, Arat M, Jurado M, Bermudez A, Labussière-Wallet H, Villalba M, Ciceri F, Martinez C, Nagler A, Sureda A, Glass B.
    Transplant Cell Ther; 2024 Feb 01; 30(2):210.e1-210.e14. PubMed ID: 38043802
    [Abstract] [Full Text] [Related]

  • 20. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
    Theurich S, Fischmann H, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Scheid C, Skoetz N, von Bergwelt-Baildon M.
    Cochrane Database Syst Rev; 2012 Sep 12; (9):CD009159. PubMed ID: 22972135
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.